On June 8, Novo Nordisk fell 3.07% in regular trading, trading at $41.5/share, with trading volume of $208 million. The decline came as the stock diverged sharply from competitor Eli Lilly, which rose 3.85% in the same session.

Multiple competitive headwinds are converging on Novo Nordisk. At the recent ADA Scientific Sessions, Eli Lilly presented retatrutide Phase 3 data showing up to 28.3% maximum weight loss, significantly outperforming Novo Nordisk's CagriSema at 22.7%. Meanwhile, semaglutide patents are expiring across multiple regions, with Brazil already approving an Ozempic generic priced 30% lower. The company has acknowledged that generic competition will reduce sales this year.

While Novo Nordisk's oral Wegovy has reached 3 million prescriptions since its January launch, and the company expanded into the UAE as its first international market for the oral version, these positives have been overshadowed by intensifying pipeline competition and pricing pressure from both branded rivals and generics entering key emerging markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)